Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer

Breast Cancer Clinical Trial

— BiOnHER  

Official title:

Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer (BiOnHER)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05912062
• Other study ID #: PI20/00544
• Status: Recruiting
• Start date: March 22, 2021
• Est. completion date: December 1, 2024

Study information

• Verified date: September 2023
• Source: Institut Català d'Oncologia
• Contact: Sonia Pernas, MD PhD
• Phone: +34932607744
• Email: contactfortrials_lh[@]iconcologia.net
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Non-randomized, open label, translational research study in women with early HER2-positive invasive breast carcinoma eligible for neoadjuvant treatment. The aim of BIONHER is to assess the impact of short-term neoadjuvant dual HER2-blockade on HER2-positive breast cancer transcriptomic profile and to evaluate whether early on treatment tumor biopsy can improve the accuracy of predicting response over the pre-treatment alone.

Description:

This is a prospective study of paired tumor samples from patients with newly diagnosed HER2-positive breast cancer eligible for neoadjuvant treatment to evaluate whether early on-treatment biomarkers can improve the accuracy of predicting response over pre-treatment samples alone. Sequential tumor biopsies will be obtained at two time points: before initiation of neoadjuvant dual HER2-blockade (pre-treatment, day 1) and 1 week later (day 8), before introduction of paclitaxel to the neoadjuvant treatment. Following the completion of neoadjuvant paclitaxel, trastuzumab and pertuzumab (THP) for 16 weeks, patients will proceed to surgery. After surgery, adjuvant treatment (including need for Anthracyclines) will be followed as per clinical practice. The study will comprise two phases: a discovery phase (n=60) where sequential paired tumor biopsies will be used for RNA-Seq analysis and assessment of tumor infiltrating lymphocytes (TILs) and CelTIL score. Radiomic characteristics of MRI, HER2Dx® and spatial transcriptomics (using GeoMx®) will be also evaluated. This phase will be followed by a validation phase (n=20) in which prediction accuracy observed in the discovery phase will be validated by Nanostring gene expression analysis using a new cohort of patients with HER2-positive breast cancer eligible for neoadjuvant therapy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: December 1, 2024
• Est. primary completion date: June 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent prior to beginning specific protocol procedures
• Untreated invasive breast carcinoma eligible for neoadjuvant treatment
• Histologically or cytologically confirmed human epidermal growth factor receptor 2 positive (HER2) Breast Cancer defined by ASCO/CAP guidelines based on the most recent analyzed biopsy or other pathology specimen; independently for estrogen receptor (ER) and progesterone receptor (PR)
• Female and male patients
• Age =18 years
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Adequate organ function defined as: Absolute neutrophil count (ANC) =1.5 × 109/L, Hemoglobin (Hgb) =10 g/dL, Platelets >100 000/mm3, Creatinine =1.6 mg/dL, ALT and AST =2.5 × ULN, Alkaline phosphatase =5 ULN, Total bilirubin =1.5 mg/dL
• Baseline LVEF =50% measured by echocardiography (ECHO) or Multiple Gate Acquisition (MUGA) scan
• Negative ß-HCG pregnancy test (serum) for premenopausal women of reproductive capacity (those who are biologically capable of having children) and for women less than 12 months after the menopause. All subjects who are biologically capable of having children must agree and commit to the use of a reliable method of birth control from 2 weeks before administration of the first dose of investigational product until 28 days after last dose of investigational product
• Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

Exclusion Criteria:

• Known metastatic disease
• Known or suspected hypersensitivity reaction to any investigational or therapeutic compound or their incorporated substances
• Concurrent congestive heart failure or LVEF <50%
• History of significant comorbidities that, in the judgment of the investigator, may interfere with the conduction of the study, the evaluation of response, or with informed consent
• Use of any investigational agent or participation in another therapeutic clinical trial concurrently or in the previous 30 days before the enrollment
• Patients who are pregnant or breast-feeding
• Women of child-bearing potential who are unable or unwilling to use contraceptive measures
• Inability or unwillingness to abide by the study protocol or cooperate fully with the investigator
• Concurrent neoadjuvant cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy other than the trial therapies)

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• HER2-positive Breast Cancer
• Neoplasms

Intervention

Drug:
• Trastuzumab (neoadjuvant)
Trastuzumab loading dose at 8mg/kg at day 1 followed by Trastuzumab at 6mg/kg in a 21-day cycle for six cycles
• Pertuzumab (neoadjuvant)
Pertuzumab loading dose at 840mg at day 1 followed by Pertuzumab at 420mg in a 21-day cycle for six cycles
• Paclitaxel (neoadjuvant)
Paclitaxel starting at day 8 at 80mg/m2, days 1, 8, and 15 of a 21-day cycle for up to fifteen weeks

Locations

Country	Name	City	State
Spain	Institut Català d'Oncologia l'Hospitalet	Hospitalet de Llobregat	Barcelona

Sponsors (5)

Lead Sponsor	Collaborator
Institut Català d'Oncologia	Fundación Sociedad Española de Oncologia Médica, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Instituto de Salud Carlos III, Reveal Genomics (Registered trademark)

Country where clinical trial is conducted

Spain, 

References & Publications (1)

Pernas S, Guerriero JL, Naumenko S, Goel S, Regan MM, Hu J, Harrison BT, Lynce F, Lin NU, Partridge A, Morikawa A, Hutchinson J, Mittendorf EA, Sokolov A, Overmoyer B. Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer. Ther Adv Med Oncol. 2022 Jul 30;14:17588359221113269. doi: 10.1177/17588359221113269. eCollection 2022. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in gene expression (by RNA-seq technology) induced by a single dose of dual HER2-blockade with pertuzumab and trastuzumab.		Between day 1 and day 8
Secondary	Gene expression patterns (by RNA-seq technology) induced by a single dose of dual HER2-blockade with pertuzumab and trastuzumab to better predict pathological complete response (pCR) in HER2-positive breast cancer		Between day 1 and day 8
Secondary	Characterize the immune component of the tumor microenvironment (TME) using Spatial transcriptomics.		Between day 1 and day 8
Secondary	Changes in the immune component of TME induced early by treatment after the first dose of dual anti-HER2 blockade that are associated with pCR.		Between day 1 and day 8
Secondary	Clinical and radiomic characteristics of MRI together with machine learning for a better prediction of which patients will achieve a pCR and which will not		Between MRI at diagnosis and pre-surgery
Secondary	Machine learning for a construction and validation of (by Nanostring technology) an early predictor of response to the neoadjuvant treatment to distinguish between responders and nonresponders.		Between day 1 and day 8